What did @i.am.elizabeth.love actually say?
The creator, 42 years old and self-described as busy, says she found a telehealth platform called M8trix Health that offered a personalized solution. She says the platform provides "expertise in hormone replacement therapy, peptide therapy, medical weight loss, and thyroid management." She frames all of this as a "health transformation." To be clear, this is a promotional video, not a personal health story with clinical detail. She makes no specific medical claims about dosing, diagnoses, or outcomes beyond the vague promise of transformation.
That framing matters. The video is soft advertising dressed as a personal testimonial. There is nothing technically wrong with that format, but viewers should register that the claims being evaluated here belong to M8trix Health's positioning, not to any independently documented patient experience.
Does the science back this up?
Some of it does, some of it does not, and some of it is impossible to evaluate from a promotional video. Hormone replacement therapy in perimenopausal women has genuine clinical support. Peptide therapy is a much murkier category. The science is real in places but the marketing around it outruns the evidence significantly.
On HRT for women in perimenopause: the 2022 updated Menopause Society position statement affirmed that hormone therapy is appropriate for healthy women under 60 or within 10 years of menopause onset, with benefits for vasomotor symptoms, bone density, and quality of life (The Menopause Society, 2022, Menopause). Testosterone specifically for women is a different story. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davis et al., 2019, Journal of Clinical Endocrinology and Metabolism) found evidence for benefit in hypoactive sexual desire disorder but noted that data for broader "optimization" claims is limited. Thyroid management via telehealth is clinically reasonable when labs and follow-up are part of the protocol. Medical weight loss is a broad category ranging from evidence-based GLP-1 therapy to unregulated supplements.
What did they get wrong (or right)?
The creator gets credit for not making specific false claims. She does not say HRT cures anything, does not quote a dose, and does not claim a compounded product is equivalent to a brand-name drug. That discipline, whether intentional or coached, keeps this video out of the most dangerous territory.
What she gets wrong, or at least incomplete, is the implication that "personalized" hormone optimization is a settled, risk-free category of medicine. The word "optimal" appears in the video as a destination rather than a contested clinical target. There is no consensus definition of "optimal" hormone levels for women in midlife. Treating lab numbers rather than symptoms is a practice pattern that regulatory bodies including the Endocrine Society have cautioned against. The promise of a "health transformation" from a telehealth intake process glosses over the reality that HRT requires ongoing monitoring, dose adjustment, and individualized risk assessment, particularly for women with cardiovascular or breast cancer risk factors (Stuenkel et al., 2015, Journal of Clinical Endocrinology and Metabolism).
Peptide therapy gets a passing mention with zero qualification. Several peptides marketed through telehealth platforms currently lack FDA approval for the indications they are marketed for. That omission is a problem.
What should you actually know?
If you are a woman in your late 30s or 40s experiencing symptoms of perimenopause, speaking to a clinician about hormone therapy is a reasonable and well-supported step. The evidence for symptom relief is real. But "optimization" framing, meaning chasing specific hormone numbers rather than addressing symptoms, is not the same thing as evidence-based HRT, and the two should not be conflated.
Telehealth hormone clinics vary enormously in quality. Some operate with rigorous lab protocols, licensed physicians, and appropriate follow-up. Others function as subscription services designed to keep you on a protocol regardless of clinical need. Before starting any hormone therapy through a telehealth platform, ask specifically who reviews your labs, what the follow-up protocol looks like, and whether the prescribing clinician is board-certified in endocrinology, OB-GYN, or a related specialty.
On peptides: the FDA has placed several previously compounded peptides, including BPC-157 and some growth hormone secretagogues, on lists of drugs that cannot be compounded under federal law. If a telehealth platform is offering peptide therapy, ask for the specific compound, its regulatory status, and the evidence base for your specific indication. A reputable provider will answer those questions without hesitation.